FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036693713> ?p ?o ?g. }

• W3036693713 abstract "We assessed the surrogacy of objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS) for overall survival (OS) in anti-PD-1/PD-L1 trials of metastatic melanoma through a meta-analysis of randomized controlled trials (RCTs).PubMed and EMBASE were searched for phase II/III RCTs till June 2019 investigating anti-PD-1/PD-L1 agents. Treatment effect (hazard ratio or odds ratio) on potential surrogates (ORR/DCR/PFS) and OS were collected. At trial level, we assessed the correlation between treatment effect on potential surrogates and OS, weighted by sample size, fixed and random effect models, and calculated the surrogate threshold effect (STE). Sensitivity analyses and leave-one-out cross-validation approach were performed to evaluate the robustness of our findings.We included 8 RCTs (4110 patients; 11 comparisons). We did not identify strong correlations between ORR [coefficient of determination (R2): 0.09-0.25], DCR (0.41-0.57) and OS. However, we noted a strong correlation between PFS and OS, with R2 of 0.82 in sample size, 0.75 in fixed effect and 0.72 in random effect model weighting, the robustness of which was further verified by leave-one-out cross-validation approach. Sensitivity analyses with restriction to trials with less than 50% crossover, phase III trials, large trials and first-line trials strengthened the correlation (0.78-0.94). The STE for PFS was 0.78.PFS may be the appropriate surrogate for OS in anti-PD-1/PD-L1 trials of metastatic melanoma. A future anti-PD-1/PD-L1 trial would need less than 0.78 for PFS of the upper limit of confidence interval to predict an OS benefit." @default.
• W3036693713 created "2020-06-25" @default.
• W3036693713 creator A5001577811 @default.
• W3036693713 creator A5017784122 @default.
• W3036693713 creator A5017943466 @default.
• W3036693713 creator A5027862454 @default.
• W3036693713 creator A5036744599 @default.
• W3036693713 creator A5037015805 @default.
• W3036693713 creator A5055765928 @default.
• W3036693713 creator A5067391199 @default.
• W3036693713 creator A5069651421 @default.
• W3036693713 creator A5076021003 @default.
• W3036693713 creator A5088098763 @default.
• W3036693713 creator A5090869718 @default.
• W3036693713 date "2020-01-01" @default.
• W3036693713 modified "2023-10-18" @default.
• W3036693713 title "Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma" @default.
• W3036693713 cites W2007753377 @default.
• W3036693713 cites W2008091096 @default.
• W3036693713 cites W2021135937 @default.
• W3036693713 cites W2066671159 @default.
• W3036693713 cites W2100158834 @default.
• W3036693713 cites W2101571970 @default.
• W3036693713 cites W2107328434 @default.
• W3036693713 cites W2116046724 @default.
• W3036693713 cites W2123363005 @default.
• W3036693713 cites W2128758225 @default.
• W3036693713 cites W2129991620 @default.
• W3036693713 cites W2131133076 @default.
• W3036693713 cites W2153778867 @default.
• W3036693713 cites W2296049142 @default.
• W3036693713 cites W2519279652 @default.
• W3036693713 cites W2560367415 @default.
• W3036693713 cites W2572174216 @default.
• W3036693713 cites W2578528809 @default.
• W3036693713 cites W2592144107 @default.
• W3036693713 cites W2605233023 @default.
• W3036693713 cites W2726861941 @default.
• W3036693713 cites W2747107882 @default.
• W3036693713 cites W2763265527 @default.
• W3036693713 cites W2766729634 @default.
• W3036693713 cites W2783760762 @default.
• W3036693713 cites W2784235889 @default.
• W3036693713 cites W2791483720 @default.
• W3036693713 cites W2888298425 @default.
• W3036693713 cites W2888914203 @default.
• W3036693713 cites W2891266481 @default.
• W3036693713 cites W2896600825 @default.
• W3036693713 cites W2898510820 @default.
• W3036693713 cites W2900498974 @default.
• W3036693713 cites W2948740360 @default.
• W3036693713 cites W2949375297 @default.
• W3036693713 cites W4211223138 @default.
• W3036693713 doi "https://doi.org/10.1177/1758835920929583" @default.
• W3036693713 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7301660" @default.
• W3036693713 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32595775" @default.
• W3036693713 hasPublicationYear "2020" @default.
• W3036693713 type Work @default.
• W3036693713 sameAs 3036693713 @default.
• W3036693713 citedByCount "1" @default.
• W3036693713 countsByYear W30366937132022 @default.
• W3036693713 crossrefType "journal-article" @default.
• W3036693713 hasAuthorship W3036693713A5001577811 @default.
• W3036693713 hasAuthorship W3036693713A5017784122 @default.
• W3036693713 hasAuthorship W3036693713A5017943466 @default.
• W3036693713 hasAuthorship W3036693713A5027862454 @default.
• W3036693713 hasAuthorship W3036693713A5036744599 @default.
• W3036693713 hasAuthorship W3036693713A5037015805 @default.
• W3036693713 hasAuthorship W3036693713A5055765928 @default.
• W3036693713 hasAuthorship W3036693713A5067391199 @default.
• W3036693713 hasAuthorship W3036693713A5069651421 @default.
• W3036693713 hasAuthorship W3036693713A5076021003 @default.
• W3036693713 hasAuthorship W3036693713A5088098763 @default.
• W3036693713 hasAuthorship W3036693713A5090869718 @default.
• W3036693713 hasBestOaLocation W30366937131 @default.
• W3036693713 hasConcept C105795698 @default.
• W3036693713 hasConcept C126322002 @default.
• W3036693713 hasConcept C129848803 @default.
• W3036693713 hasConcept C141341695 @default.
• W3036693713 hasConcept C143998085 @default.
• W3036693713 hasConcept C168563851 @default.
• W3036693713 hasConcept C168743327 @default.
• W3036693713 hasConcept C207103383 @default.
• W3036693713 hasConcept C2777658100 @default.
• W3036693713 hasConcept C33923547 @default.
• W3036693713 hasConcept C44249647 @default.
• W3036693713 hasConcept C502942594 @default.
• W3036693713 hasConcept C535046627 @default.
• W3036693713 hasConcept C71924100 @default.
• W3036693713 hasConcept C95190672 @default.
• W3036693713 hasConceptScore W3036693713C105795698 @default.
• W3036693713 hasConceptScore W3036693713C126322002 @default.
• W3036693713 hasConceptScore W3036693713C129848803 @default.
• W3036693713 hasConceptScore W3036693713C141341695 @default.
• W3036693713 hasConceptScore W3036693713C143998085 @default.
• W3036693713 hasConceptScore W3036693713C168563851 @default.
• W3036693713 hasConceptScore W3036693713C168743327 @default.
• W3036693713 hasConceptScore W3036693713C207103383 @default.
• W3036693713 hasConceptScore W3036693713C2777658100 @default.
• W3036693713 hasConceptScore W3036693713C33923547 @default.

• next